WuXi Biologics subsidiary WuXi Vaccines has agreed to sell its vaccine manufacturing facility in Dundalk, Ireland, to MSD for approximately $500m. Expected to close in the first half of 2025 ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

MSD has expanded its presence in Ireland with an agreement to buy a vaccine manufacturing facility from Chinese biotech WuXi Biologics for around €500 million (around $520 million). The plant in ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

Pharmaceutical firm MSD has agreed a deal to buy the WuXi Vaccines manufacturing facility in Dundalk, Co Louth as part of its long-term plans in Ireland. MSD said the deal is worth €500m and ...

In Ireland, WuXi Biologics has sold a new vaccine plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi ...

The acquisition brings Merck’s total locations in Ireland to eight, covering Carlow, Cork, Dublin, Louth, Meath and Tipperary. Over 3,000 people are employed across the network. Merck and WuXi ...

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...

announced on 06 January the sale of its WuXi Vaccines facility in Ireland to MSD International, a subsidiary of Merck & Co. for approximately 500 million USD. Arne Dedert/dpa WuXi Biologics ...